Age Threshold of 50 for New Zoster Vaccine Not Cost-Effective: Study

Share this post

The new Advisory Committee on Immunization Practices (ACIP) guideline that recommends the new recombinant adjuvanted zoster subunit vaccine (RZV) over the live attenuated zoster vaccine (ZVL) and lowers the vaccination age to 50 years is not cost-effective, according to a new analysis.
Reuters Health Information

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply